CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer

Lau, Asa P. Y.; Khavkine Binstock, Sharon S.; Thu, Kelsie L.

doi:10.3390/cancers15215229

Cited by 3 publications

(1 citation statement)

References 288 publications

(463 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, regulating Hsp100 activity can hinder the process associated with viral replication, and the function of caspase proteins in regulating cell death and inflammation emphasizes the promise of apoptosis protein inhibitors to mitigate tissue injuries and enhance therapeutic outcomes ( 76 , 95 , 97 , 98 ). Furthermore, focusing CD47 on improving immunological cell detection and eliminating diseased cells could enhance the host organism against viruses’ immune defenses ( 99–101 ). Hence, it is important to comprehend the interaction between these protein markers and various immunological routes, which culminates in the evolvement of in-depth and efficient treatment regimens.…”

Section: Discussionmentioning

confidence: 99%

Feline coronavirus influences the biogenesis and composition of extracellular vesicles derived from CRFK cells

Wijerathne,

Pandit,

Ipinmoroti

et al. 2024

Front. Vet. Sci.

View full text Add to dashboard Cite

IntroductionCoronavirus (CoV) has become a public health crisis that causes numerous illnesses in humans and certain animals. Studies have identified the small, lipid-bound structures called extracellular vesicles (EVs) as the mechanism through which viruses can enter host cells, spread, and evade the host’s immune defenses. EVs are able to package and carry numerous viral compounds, including proteins, genetic substances, lipids, and receptor proteins. We proposed that the coronavirus could alter EV production and content, as well as influence EV biogenesis and composition in host cells.MethodsIn the current research, Crandell-Rees feline kidney (CRFK) cells were infected with feline coronavirus (FCoV) in an exosome-free media at a multiplicity of infection (MOI) of 2,500 infectious units (IFU) at 48 h and 72 h time points. Cell viability was analyzed and found to be significantly decreased by 9% (48 h) and 15% (72 h) due to FCoV infection. EVs were isolated by ultracentrifugation, and the surface morphology of isolated EVs was analyzed via Scanning Electron Microscope (SEM).ResultsNanoSight particle tracking analysis (NTA) confirmed that the mean particle sizes of control EVs were 131.9 nm and 126.6 nm, while FCoV infected-derived EVs were 143.4 nm and 120.9 nm at 48 and 72 h, respectively. Total DNA, RNA, and protein levels were determined in isolated EVs at both incubation time points; however, total protein was significantly increased at 48 h. Expression of specific protein markers such as TMPRSS2, ACE2, Alix, TSG101, CDs (29, 47, 63), TLRs (3, 6, 7), TNF-α, and others were altered in infection-derived EVs when compared to control-derived EVs after FCoV infection.DiscussionOur findings suggested that FCoV infection could alter the EV production and composition in host cells, which affects the infection progression and disease evolution. One purpose of studying EVs in various animal coronaviruses that are in close contact with humans is to provide significant information about disease development, transmission, and adaptation. Hence, this study suggests that EVs could provide diagnostic and therapeutic applications in animal CoVs, and such understanding could provide information to prevent future coronavirus outbreaks.

show abstract

Section: Discussionmentioning

confidence: 99%

Feline coronavirus influences the biogenesis and composition of extracellular vesicles derived from CRFK cells

Wijerathne,

Pandit,

Ipinmoroti

et al. 2024

Front. Vet. Sci.

View full text Add to dashboard Cite

show abstract

Therapeutic strategies targeting CD47-SIRPα signaling pathway in gastrointestinal cancers treatment

Che,

Wang,

Zhang

et al. 2024

Journal of Pharmaceutical Analysis

View full text Add to dashboard Cite

Proteomic Investigation of Immune Checkpoints and Some of Their Inhibitors

Agostini,

Traldi,

Hamdan

2024

IJMS

View full text Add to dashboard Cite

Immune checkpoints are crucial molecules for the maintenance of antitumor immune responses. The activation or inhibition of these molecules is dependent on the interactions between receptors and ligands; such interactions can provide inhibitory or stimulatory signals to the various components of the immune system. Over the last 10 years, the inhibition of immune checkpoints, such as cytotoxic T lymphocyte antigen-4, programmed cell death-1, and programmed cell death ligand-1, has taken a leading role in immune therapy. This relatively recent therapy regime is based on the use of checkpoint inhibitors, which enhance the immune response towards various forms of cancer. For a subset of patients with specific forms of cancer, these inhibitors can induce a durable response to therapy; however, the medium response rate to such therapy remains relatively poor. Recent research activities have demonstrated that the disease response to this highly promising therapy resembles the response of many forms of cancer to chemotherapy, where an encouraging initial response is followed by acquired resistance to treatment and progress of the disease. That said, these inhibitors are now used as single agents or in combination with chemotherapies as first or second lines of treatment for about 50 types of cancer. The prevailing opinion regarding immune therapy suggests that for this approach of therapy to deliver on its promise, a number of challenges have to be circumvented. These challenges include understanding the resistance mechanisms to immune checkpoint blockade, the identification of more efficient inhibitors, extending their therapeutic benefits to a wider audience of cancer patients, better management of immune-related adverse side effects, and, more urgently the identification of biomarkers, which would help treating oncologists in the identification of patients who are likely to respond positively to the immune therapies and, last but not least, the prices of therapy which can be afforded by the highest number of patients. Numerous studies have demonstrated that understanding the interaction between these checkpoints and the immune system is essential for the development of efficient checkpoint inhibitors and improved immune therapies. In the present text, we discuss some of these checkpoints, their inhibitors, and some works in which mass spectrometry-based proteomic analyses were applied.

show abstract

CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer

Cited by 3 publications

References 288 publications

Feline coronavirus influences the biogenesis and composition of extracellular vesicles derived from CRFK cells

Feline coronavirus influences the biogenesis and composition of extracellular vesicles derived from CRFK cells

Therapeutic strategies targeting CD47-SIRPα signaling pathway in gastrointestinal cancers treatment

Proteomic Investigation of Immune Checkpoints and Some of Their Inhibitors

Contact Info

Product

Resources

About